The Ebola outbreak in the Democratic Republic of Congo has killed more than 5,000 people. Authorities are struggling to contain the outbreak because no treatments or vaccines have been approved.
10:51 PMAl Jazeera16 stories from 7 sources
Outbreak mortality and access fights dominate a fragmented health day
Day’s Recap
Supporting Articles
A new estimate puts annual deaths from venomous snakebites between 274,000 and 513,000 worldwide, far above official counts, with up to 7 million people suffering envenoming and more than 800,000 survivors left disabled.
6:37 AMScienceDaily
A US district judge blocked a Trump administration Medicaid rule that required some people with illnesses to prove that their conditions impaired their ability to work. The ruling followed a lawsuit brought by 25 states and the District of Columbia.
12:38 AMAl Jazeera
The arbitration system created by the No Surprises Act has generated more than 2 million disputes, far above the roughly 17,000 annual cases originally projected. Researchers estimate that the process cost health plans $22.4 billion during the law’s first four years.
4:00 AMFortune10:51 PMAl Jazeera
Ebola death toll in DR Congo passes 5,000
Summary
The Ebola outbreak in the Democratic Republic of Congo has killed more than 5,000 people. Authorities are struggling to contain the outbreak because no treatments or vaccines have been approved.
The death toll shows that containment efforts are failing at a large scale, while the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The outbreak is expanding faster than health authorities can control it, with no approved vaccine or treatment to reduce fatalities.
6:37 AMScienceDaily
Scientists reveal a hidden snakebite crisis killing up to 513,000 people a year
Summary
A new estimate puts annual deaths from venomous snakebites between 274,000 and 513,000 worldwide, far above official counts, with up to 7 million people suffering envenoming and more than 800,000 survivors left disabled.
The scale of undercounting points to a major failure in surveillance, treatment access, and antivenom
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Snakebite is an underfunded emergency whose mortality and disability burden may rival that of far better-known diseases.
12:38 AMAl Jazeera
US judge blocks Trump’s Medicaid rule forcing ill to prove impairment
Summary
A US district judge blocked a Trump administration Medicaid rule that required some people with illnesses to prove that their conditions impaired their ability to work. The ruling followed a lawsuit brought by 25 states and the District of Columbia.
The ruling pauses a new eligibility barrier for Medicaid recipients whose health conditions may limit
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The decision preserves Medicaid access for potentially vulnerable patients while the legality of the work-related requirement is litigated.
4:00 AMFortune
The U.S. expected 17,000 disputes a year when it passed this medical bills law. It gets over 2 million instead
Summary
The arbitration system created by the No Surprises Act has generated more than 2 million disputes, far above the roughly 17,000 annual cases originally projected. Researchers estimate that the process cost health plans $22.4 billion during the law’s first four years.
The dispute process has become a central cost of the law rather than a limited
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A protection designed to resolve surprise bills may itself be driving higher health system costs and regulatory strain.
Other Developments
A curated list of other prominent stories from this day.
Amazon said Amazon Pharmacy usage rose more than 60% year over year, with repeat customers also increasing, as consumers use the platform for everyday health needs, refills, and prescriptions. The company is expanding pharmacy inside the same app customers already use for retail purchases.
1:41 PMPYMNTS
Research links election-related stress with irregular heart rhythms and increased heart attack risk, suggesting that political events can produce measurable cardiovascular effects.
10:07 AMStat News
The discussion examines new cancer data presented at the European Society for Medical Oncology meeting, including results involving Merck and Moderna's mRNA cancer vaccine.
9:33 AMStat News
A new Lancet series examines why men experience worse health outcomes than women despite holding social and economic advantages in many settings.
9:12 AMStat News
An intensive program combining a low-calorie diet with structured exercise put 54% of adults under 45 with type 2 diabetes into remission after six months, compared with 4% receiving usual care.
8:12 AMScienceDaily
A private equity-backed company now owns every methadone clinic in Montana. The broader pattern is consolidation: private equity has bought existing treatment capacity rather than building new clinics.
7:49 AMFortune
Researchers found aggressive cancer cells hidden within childhood rhabdomyosarcoma tumors that had been classified as lower risk, offering a possible explanation for unexpected treatment failures and deaths.
6:15 AMScienceDaily
Federal health officials are working to prevent a regulatory conflict as more states pursue AI trials in clinical care. The emerging dispute centers on how authority should be divided between state experimentation and federal oversight.
4:30 AMStat News
Patients who sought care for seemingly routine problems, including infections and respiratory symptoms, received emergency department bills instead of the urgent care treatment they expected. The resulting charges reached thousands of dollars.
4:30 AMStat News
A medical historian uses an 1834 letter about a measles outbreak to examine arguments that resemble those used by today’s anti-vaccine movement. The comparison suggests that distrust of public health measures has older roots than current political debates.
4:30 AMStat News
Dis-Chem Pharmacies said strong demand for GLP-1 drugs is driving double-digit growth in dispensary revenue. South Africans are increasingly buying the costly medicines for diabetes and obesity treatment.
2:48 AMBloomberg MarketsNovartis is moving beyond the loss of exclusivity for a major drug, but disappointing clinical data and other trial setbacks have weakened its pipeline. The company now faces pressure to replace future blockbuster revenue before its next patent expiration arrives.
2:00 AMCNBC1:41 PMPYMNTS
Amazon Fills the Prescription ChatGPT Can’t
Summary
Amazon said Amazon Pharmacy usage rose more than 60% year over year, with repeat customers also increasing, as consumers use the platform for everyday health needs, refills, and prescriptions. The company is expanding pharmacy inside the same app customers already use for retail purchases.
The growth gives Amazon a practical advantage over conversational AI: it can connect health questions
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Amazon is turning pharmacy from an add-on into a distribution channel that links consumer convenience with prescription volume.
10:07 AMStat News
How Election Day can affect your heart
Summary
Research links election-related stress with irregular heart rhythms and increased heart attack risk, suggesting that political events can produce measurable cardiovascular effects.
The risk appears to come from acute stress layered onto existing cardiovascular vulnerability, not from
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Election stress can become a real short-term health risk for people already vulnerable to cardiovascular events.
9:33 AMStat News
Assessing Merck and Moderna’s mRNA cancer vaccine
Summary
The discussion examines new cancer data presented at the European Society for Medical Oncology meeting, including results involving Merck and Moderna's mRNA cancer vaccine.
The key question is whether the vaccine can produce durable benefits beyond the initial trial
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Positive results could establish personalized mRNA vaccines as a new cancer treatment platform, but the clinical and logistical hurdles remain substantial.
9:12 AMStat News
The persisting paradox of men’s health
Summary
A new Lancet series examines why men experience worse health outcomes than women despite holding social and economic advantages in many settings.
The disparity cannot be explained by biology alone; riskier behaviors, lower use of preventive care,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Improving men's health requires changing both care access and the social patterns that discourage prevention.
8:12 AMScienceDaily
Type 2 diabetes breakthrough as 54% achieve remission in just 6 months
Summary
An intensive program combining a low-calorie diet with structured exercise put 54% of adults under 45 with type 2 diabetes into remission after six months, compared with 4% receiving usual care.
The large gap suggests that early, intensive lifestyle treatment can materially change the course of
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Remission may be achievable for many younger patients, but access to intensive lifestyle care will determine whether the finding changes routine treatment.
7:49 AMFortune
One private equity–backed company owns every methadone clinic in Montana
Summary
A private equity-backed company now owns every methadone clinic in Montana. The broader pattern is consolidation: private equity has bought existing treatment capacity rather than building new clinics.
Ownership concentration gives one company outsized control over access to methadone treatment across the state.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A single private equity-backed owner controlling all of Montana’s methadone clinics turns addiction treatment access into a statewide dependency on one corporate operator.
6:15 AMScienceDaily
Why some “lower-risk” childhood cancers turn deadly
Summary
Researchers found aggressive cancer cells hidden within childhood rhabdomyosarcoma tumors that had been classified as lower risk, offering a possible explanation for unexpected treatment failures and deaths.
The discovery challenges risk categories based on the overall appearance of a tumor and could
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
More precise risk assessment could reduce both undertreatment of dangerous tumors and overtreatment of children with less aggressive disease.
4:30 AMStat News
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Summary
Federal health officials are working to prevent a regulatory conflict as more states pursue AI trials in clinical care. The emerging dispute centers on how authority should be divided between state experimentation and federal oversight.
State-level deployment is moving faster than regulators can establish a coherent national framework. A patchwork
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The fight over jurisdiction could shape how quickly clinical AI reaches patients and under what safeguards.
4:30 AMStat News
STAT+: How a simple UTI turns into a $1,756 bill
Summary
Patients who sought care for seemingly routine problems, including infections and respiratory symptoms, received emergency department bills instead of the urgent care treatment they expected. The resulting charges reached thousands of dollars.
The core problem is not the medical complexity of these visits but the mismatch between
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Unexpected emergency billing makes routine care financially risky and weakens patients’ ability to shop for affordable treatment.
4:30 AMStat News
Opinion: What a mother’s 1834 letter about measles tells us about MAHA
Summary
A medical historian uses an 1834 letter about a measles outbreak to examine arguments that resemble those used by today’s anti-vaccine movement. The comparison suggests that distrust of public health measures has older roots than current political debates.
The historical record complicates claims that vaccine skepticism is a uniquely modern reaction to institutions
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Understanding the movement’s historical continuity matters because its arguments can persist even when the original disease threat becomes less visible.
2:48 AMBloomberg Markets
GLP-1 Demand Boosts Dis-Chem’s South Africa Pharmacy Revenue
Summary
Dis-Chem Pharmacies said strong demand for GLP-1 drugs is driving double-digit growth in dispensary revenue. South Africans are increasingly buying the costly medicines for diabetes and obesity treatment.
GLP-1 drugs are becoming a meaningful revenue engine for pharmacies, not just a pharmaceutical growth
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
GLP-1 adoption is reshaping pharmacy economics while exposing a widening access gap in obesity and diabetes care.
2:00 AMCNBC
A pharma giant is moving past one patent cliff — but another is already looming
Summary
Novartis is moving beyond the loss of exclusivity for a major drug, but disappointing clinical data and other trial setbacks have weakened its pipeline. The company now faces pressure to replace future blockbuster revenue before its next patent expiration arrives.
Novartis has less time to build its next growth cycle than its current earnings may
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The episode shows how clinical setbacks can turn a manageable patent transition into a broader growth problem.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!